Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2016
>
Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal
Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal
Read also
Litfulo Phase III data support Pfizer’s push into systemic vitiligo treatment
Pfizer's Phase III trials demonstrate Litfulo's efficacy in nonsegmental vitiligo, supporting its plan to submit data to global regulatory authorities.
Experimental cancer drug works differently than researchers originally thought
A study reveals that the experimental cancer drug zavondemstat blocks the DHODH enzyme rather than KDM4, altering our understanding of its mechanism.
Bayer pledges $2.2bn to US manufacturing facility
Bayer has committed $2.2 billion to build a new, modular pharmaceutical manufacturing campus in Ohio, expected to serve global and domestic markets.
Click claims FDA okay for first-in-class schizophrenia DTx
Click Therapeutics received FDA clearance for Motivista, a digital therapeutic shown to significantly reduce negative symptoms in schizophrenia patients.
